The effect of zofenopril on the cardiovascular system of spontaneously hypertensive rats treated with the ACE2 inhibitor MLN-4760.

Abstract

BACKGROUND:

Angiotensin converting enzyme 2 (ACE2) plays a crucial role in the infection cycle of SARS-CoV-2 responsible for formation of COVID-19 pandemic. In the cardiovascular system, the virus enters the cells by binding to the transmembrane form of ACE2 causing detrimental effects especially in individuals with developed hypertension or heart disease. Zofenopril, a H2S-releasing angiotensin-converting enzyme inhibitor (ACEI), has been shown to be effective in the treatment of patients with essential hypertension; however, in conditions of ACE2 inhibition its potential beneficial effect has not been investigated yet. Therefore, the aim of the study was to determine the effect of zofenopril on the cardiovascular system of spontaneously hypertensive rats, an animal model of human essential hypertension and heart failure, under conditions of ACE2 inhibition induced by the administration of the specific inhibitor MLN-4760 (MLN).

RESULTS:

Zofenopril reduced MLN-increased visceral fat to body weight ratio although no changes in systolic blood pressure were recorded. Zofenopril administration resulted in a favorable increase in left ventricle ejection fraction and improvement of diastolic function regardless of ACE2 inhibition, which was associated with increased H2S levels in plasma and heart tissue. Similarly, the acute hypotensive responses induced by acetylcholine, L-NAME (NOsynthase inhibitor) and captopril (ACEI) were comparable after zofenopril administration independently from ACE2 inhibition. Although simultaneous treatment with zofenopril and MLN led to increased thoracic aorta vasorelaxation, zofenopril increased the NO component equally regardless of MLN treatment, which was associated with increased NO-synthase activity in aorta and left ventricle. Moreover, unlike in control rats, the endogenous H2S participated in maintaining of aortic endothelial function in MLN-treated rats and the treatment with zofenopril had no impact on this effect.

CONCLUSIONS:

Zofenopril treatment reduced MLN-induced adiposity and improved cardiac function regardless of ACE2 inhibition. Although the concomitant MLN and zofenopril treatment increased thoracic aorta vasorelaxation capacity, zofenopril increased the participation of H2S and NO in the maintenance of endothelial function independently from ACE2 inhibition. Our results confirmed that the beneficial effects of zofenopril were not affected by ACE2 inhibition, moreover, we assume that ACE2 inhibition itself can lead to the activation of cardiovascular compensatory mechanisms associated with Mas receptor, nitrous and sulfide signaling.

• Authors: Sona Cacanyiova, Martina Cebova, Fedor Simko, Tomas Baka, Iveta Bernatova, Michal Kluknavsky, Stefan Zorad, Katarina Krskova, Ezgi Shaman, Anna Zemancikova, Andrej Barta, Basak G Aydemir, Andrea Berenyiova
• Journal: Biological research (Biol Res) Vol. 56 Issue 1 Pg. 55 (Oct 25 2023) ISSN: 0717-6287 [Electronic] England
• PMID: 37875978 (Publication Type: Journal Article)
• Copyright: © 2023. Sociedad de Biologia de Chile.

Chemical References

• zofenopril
• Captopril
• 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid
• Angiotensin-Converting Enzyme 2
• Angiotensin-Converting Enzyme Inhibitors

Topics

• Humans
• Rats
• Animals
• Captopril (pharmacology)
• Rats, Inbred SHR
• Angiotensin-Converting Enzyme 2 (pharmacology)
• Pandemics
• Angiotensin-Converting Enzyme Inhibitors (pharmacology)
• Blood Pressure
• Essential Hypertension
• Cardiovascular System